# Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

> **NCT05065619** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medicago** · enrollment: 128 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** MT-2766 High dose (3.75 µg)
- **DRUG:** Placebo
- **BIOLOGICAL:** MT-2766 Low dose

## Key facts

- **NCT ID:** NCT05065619
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-02
- **Primary completion:** 2022-03-12
- **Final completion:** 2023-01-29
- **Target enrollment:** 128 (ACTUAL)
- **Why stopped:** Public vaccination of approved ancestral strain COVID-19 vaccines will be terminated soon. And boosters must be dosed after ancestral vaccination approved in Japan. The study was terminated for ethical reason to prioritize the ancestral vaccination.
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065619, "Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05065619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*